

Mehmet H. Hepgur, MD  
2121 N Ocean Blvd Apt 1206w Boca Raton, FL 33431  
Phone: (716) 352-8707 Fax (844) 612-1929  
[hepgur@gmail.com](mailto:hepgur@gmail.com)

### **Professional Experience**

Attending Hematologist/Oncologist 03/2019 – present  
Broward Health North Cancer Center  
201 East Sample Road, Deerfield Beach FL

Attending Hematologist/Oncologist 08/2015 – 3/2019  
Broward Health Medical Center  
1625 SE 3<sup>rd</sup> Avenue, Fort Lauderdale FL

Attending Hematologist/Oncologist 07/2014 – 7/2015  
Desert Regional Medical Center  
Palm Springs, CA

### **Hospital Affiliations**

Broward Health North 11/2015 - present  
201 East Sample Road  
Deerfield Beach FL

Broward Health Medical Center 06/2015 - present  
1625 SE 3<sup>rd</sup> Avenue  
Fort Lauderdale, FL

Broward Health Imperial Point 11/2017 - present  
6401 N. Federal Highway  
Fort Lauderdale, FL

### **Academic Affiliations**

Clinical Assistant Professor 05/2016 – 3/2019  
Department of Internal Medicine  
Nova Southeastern University

### **Administrative Experience**

Chairman, Cancer Committee 03/2019 – present  
Broward Health North Cancer Center

## **Post-Graduate Training**

Fellowship; Hematology/Oncology 07/2011- 06/2014  
USC Keck School of Medicine  
Norris Comprehensive Cancer Center  
Los Angeles, CA  
Program Directors: Syma Iqbal, MD and Howard Liebman, MD

Residency; Internal Medicine 06/2008-06/2011  
University at Buffalo, State University of New York  
Buffalo, NY  
Program Director: Ellen Rich, MD

## **Medical Education**

Istanbul University, Istanbul School of Medicine 08/1996-07/1999  
Istanbul, Turkey

Uludag University, School of Medicine 09/1993-07/1996  
Bursa, Turkey

## **Other Post-Graduate and Research Experience**

Research Associate 06/2009-09/2009  
Roswell Park Cancer Center  
Division of Bone Marrow Transplantation  
Division Chief: Phillip McCarthy, MD  
Buffalo, NY

Clinical Fellow; Division of Adult Reconstruction 08/2007-12/2007  
Department of Orthopedic Surgery  
University of Virginia Health System  
Charlottesville, VA  
Department Chairman: Cato T. Laurencin, MD

Clinical Fellow; Division of Trauma 08/2006-08/2007  
Department of Orthopedics  
Medical University of Ohio  
Toledo, OH  
Program Chairman: Nabil Ebraheim, MD

Clinical Fellow; Foot and Ankle Surgery 08/2005-08/2006  
American Sports Medicine Institute  
Birmingham, AL  
Program Chairman: John S. Gould, MD

Resident; Orthopedic Surgery  
University of Istanbul, Istanbul School of Medicine  
Istanbul, Turkey  
Program Director: Aziz K. Alturfan, MD

11 /1999-08/2004

### **Licensure**

State of Tennessee Medical License: June 2014, 50937, active  
State of Florida Medical License: April 2014, ME119484, active  
State of California Medical License: December 2010, A 115019, active  
DEA License: September 2013, FH2531881

### **Specialty Certifications**

Board Certification: ABIM, Medical Oncology, November 2014  
Board Certification: ABIM, Hematology, November 2014  
Board Certification: ABIM, Internal Medicine, August 2011  
ECFMG Certification: January 2006, 0-603-823-6  
Republic of Turkey Ministry of Health, Orthopedic Surgery Specialist: August 2004

### **Professional Memberships**

Southwest Oncology Group (SWOG), 2014  
American Society of Clinical Oncology, 2012  
American Society of Hematology, 2011  
American College of Physicians , 2008

### **Examinations**

USMLE Step 1 Passed (233/ 94): 03/2005  
USMLE Step 2 CK and CS Passed (251/99): 06/2005 and 10/2005  
USMLE Step 3 Passed (212 /87): 12/2006

### **Honors and Awards**

Most Valuable Physician Award, Broward Health North, 2021

Cigna Care Designated Physician, 2017

Best Research Presentation Award. USC Keck School of Medicine, Division of Medical Oncology, June 2014. Immunotherapy of mCRPC with Sipuleucel-T: Predicting Treatment Responses.

Health Grades Honor Roll, 2014

Conquer Cancer Foundation Merit Award. ASCO GU Cancers Symposium, February 2013. Changes in Circulating Tumor Cells (CTC) and Markers of Inflammation After Sipuleucel-T Treatment.

## **Editorial Positions**

Peer-reviewer; Journal of Immuno Targets and Therapy, 2014-2018

Peer-reviewer; Journal of Onco Targets and Therapy, 2014-2018

## **Lectures by Invitation**

Bleed or Not to Bleed. AACN - Broward County Chapter Annual Symposium. April, 2017.

Harnessing the Power of Immune System. Annual Day of Research and Hope, Gilda's Club South Florida, May 2016

Treatment of Metastatic Prostate Cancer with Sipuleucel-T. East Tennessee State University Quillen College of Medicine, Johnson City, TN. October 2013

Biomarkers Predicting Tumor Responses to Sipuleucel-T. Emory University School of Medicine, Atlanta, GA. October 2013

## **Publications**

1. **Hegur M**, Sadeghi S, Dorff TB, Quinn OI. Tivozanib in the treatment of renal cell carcinoma. *Biologics: Targets and Therapy*. 2013; 7: 139-148.
2. Chaudhary P, **Hegur M**, Sarkissian S, Smith RJH, Weitz IC Late Onset aHUS due to heterozygous mutations of CFH/CFHR1-3 and complement factor H 479. *Blood Transfus*. 2013; 15:1-3
3. Dorff TB, Wilkins C, **Hegur M**, Quinn DI. Durable complete remission from castration-resistant prostate cancer with Sipuleucel-T after estrogen withdrawal. *Clinical Genitourinary Cancer*. *Clin Genitourin Cancer*. 2013; 14. S1558-7673
4. **Hegur M**, Ahluwalia MS, Anne N, Thomas J, Liu H, Schiff MD, Loud PA, Hahn TE, Bullard Dunn KM, McCarthy PL Jr. Medical management of pneumatosis intestinalis in patients undergoing allogeneic blood and marrow transplantation. *Bone Marrow Transplant*. 2011; 46(6): 876-9.
5. Battiwalla M, **Hegur M**, Pan D, McCarthy PL, Ahluwalia MS, Camacho SH, Starostik P, Wallace PK. Multiparameter flow cytometry for the diagnosis and monitoring of small GPI-deficient cellular populations. *Cytometry B Clin Cytom*. 2010; 78 (5): 348-56.
6. **Hegur M**, Noor MA, DePlato A. Solitary splenic metastasis from primary non-small cell carcinoma of the lung. *Journal of Hematology and Oncology* 2010; 20 (4): 241-244.

7. Ebraheim N, Liu J, Patil V, Lee A, **Hepgur M**, Yeasting R. Evaluation of skull thickness and insertion torque at the halo pin insertion areas in the elderly. *The Spine Journal*. 2007; 7(5):139-140.
8. Sozen YV, **Hepgur M**, Kilicoglu O, Yazicioglu O. The effectiveness of arthroscopic debridement and lavage treatment in osteoarthritis of the hip: preliminary results. *Acta Orthop Traumatol Turc*. 2004; 38(2): 96-103.
9. Cetik O, Bilen FE, Sozen YV, **Hepgur M**. A 2-staged method for treatment of deep osteochondral lesions of the knee joint. *Arthroscopy*. 2001; 17(9): 35-37.
10. Sen C, Kocaoglu M, Bilen E, Dikici F, **Hepgur M**. Comparison of two different techniques for high tibial osteotomy: internal fixation vs. circular external fixator. *Acta Orthop Traumatol Turc*. 2001; 35(5): 382-389.
11. Sozen YV, Cetik E, Bilen E, **Hepgur M**. Two-stage treatment of type 4 osteochondritis dissecans of the knee. *Acta Orthop Traumatol Turc*. 2001; 35(3): 265- 269.

#### Abstracts

1. **Hepgur M**, Dorff TB, Cai J, Quinn DI. Dynamic changes in bio markers for immune response to Sipuleucel-T for metastatic castrate-resistant prostate cancer (mCRPC). *J Clin Oncol* 33, 2015 (suppl 7; abstr 181)
2. **Hepgur M**, Dorff TB, Cai J, Pinski JK, Reed M, Quinn DI. Identification of biological and inflammatory markers for predicting clinical responses to Sipuleucel-T in mCRPC. *J Clin Oncol* 32, 2014 (suppl 4; abstr 134)
3. **Hepgur M**, Dorff TB, Cai J, Pinski JK, Reed M, Luther M, Chan M, Quinn DI. Clinical and biological factors for immune response to Sipuleucel-T for metastatic castrate resistant prostate cancer. *J Clin Oncol* 32, 2014 (suppl 4; abstr 219)
4. **Hepgur M**, Dorff TB, Cai J, Pinski JK, Reed M, Luther M, Chan M, Quinn DI. Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment. *J Clin Oncol* 31, 2013 (suppl 6; abstr 40).
5. **Hepgur M**, Hu J. Ewings Sarcoma in adults: A retrospective review of dose and tolerability of treatment. *Connective Tissue Society 18<sup>th</sup> Annual Meeting*. Abstract 1773240. October 2013.
6. Kam EH, Chan BM, **Hepgur M**, Dorff TB, Quinn DI. Two year update on the evaluation of patients, safety, and efficacy of Sipuleucel-T in the treatment of metastatic castrate-resistant prostate cancer (mCRPC) at an academic teaching hospital. *HOPA Annual Meeting*; Los Angeles, CA. March 2013

7. **Hepgur M**, Chaudhary P, Sarkissian S, Smith RJH, Liebman H, Weitz IC. A novel hybrid CFH/CFHR1-3 gene in atypical hemolytic uremic syndrome. *Blood* 2012, 120: Abstract 4644.
8. **Hepgur M**, Battiwalla M, McCarthy PL, Saito N, Hahn T. Early complete Donor Lymphoid Chimerism with Fluda rabine, Melphalan and Low Dose (400 cGy) Total Body Irradiation Reduced Intensity Conditioning. *Biol Blood Marrow Transplant* 2010; 16 (Suppl 2): S291-S292.
9. **Hepgur M**, McCarthy PL, Battiwalla M, Paplham P. Atypical presentation of vaginal GvHD with abdominal pain crises. *Biol Blood Marrow Transplant* 2010; 16 (Suppl 2): S315.
10. Sozen YV, **Hepgur M**, Kilicoglu O, Sivacioglu S. Clinical results of the arthroscopic debridement and lavage in osteoarthritis of the hip. *National Orthopedics and Traumatology Congress; Istanbul, Turkey. November 2003.*
11. Eralp L, Gulabi D, Onen M, **Hepgur M**. Comparison of rotational hinged and hinged modular endoprosthesis used for reconstruction of distal femur tumor resections. *National Orthopedics and Traumatology Congress; Antalya, Turkey. November 2001.*
12. Bozan E, **Hepgur M**, Coban Z. (2003, November). Results of the in tramedullary titanium elastic nails for the fixation of femur fractures. *National Orthopedics and Traumatology Congress. Antalya, Turkey. November 2001*
13. Asik M, Bilen FE, Sen C, **Hepgur M**, Debre M. Surgical treatment of intra-articular fractures of calcaneus. *National Orthopedics and Traumatology Congress; Antalya, Turkey. November 2001*

### **Clinical Research**

1. **Alliance A011502**: A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive, HER 2 Negative Breast Cancer: The ABC Trial (**Sub-Investigator**)
2. **Alliance A011401**: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (**Sub-Investigator**)
3. **SWOG S1207**: "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer; "e3 Breast Cancer Study-evaluating everolimus with endocrine therapy" (**Primary Investigator**)
4. **NRG-CC003**: Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer (**Sub-Investigator**)

5. **Array 818-302:** A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with *BRAF* V600E- mutant Metastatic Colorectal Cancer (**Primary Investigator**)
6. **Amgen 20070782:** A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long-Term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer Receiving Multi-Cycle Chemotherapy (**Sub-Investigator**)
7. **Amgen 20060359:** A Randomized, Double-Blind, Placebo Controlled, Multicenter Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early Stage Breast Cancer at High Risk of Recurrence (D-CARE) (**Primary Investigator**)
8. **Celgene Connect MDS and AML:** The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry (**Primary Investigator**)
9. **Fujirebio FDI-68:** A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients with Pancreatic Cancer (**Primary Investigator**)
10. **Fujirebio FDI-69:** A Prospective Longitudinal Study of CA 15-3 as an Aid in Monitoring Recurrence or Progressive Disease in Patients with Breast Cancer (**Primary Investigator**)